A first-in-class peptide-based PET tracer, 18F-AlF-NOTA-PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18F-FDG. 18F ...

Resectable locally advanced head and neck squamous-cell carcinoma (HNSCC) is a burdensome disease with few treatment advances in recent decades.

What is ‘tech neck’ and how can you fix it? Holding your head at a 45-degree angle looking at a screen can feel like 50 pounds of weight, say medical experts ...

Bicara Therapeutics has unveiled updated data for its bifunctional antibody paired with Keytruda in head and neck squamous cell carcinoma (HNSCC), including a first look at overall survival (OS ...

Dr. Means, President Trump’s new pick for surgeon general, has focused on the prevalence of chronic diseases and called on the government to scale back on childhood vaccines.

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.

In part 2 of this interview, Ravindra Uppaluri, MD, PhD, director of head and neck surgical oncology at Dana-Farber Brigham Cancer Center, lead investigator of the phase 3 KEYNOTE-689 trial ...

The idea that integrating immunotherapy before surgery, number one, changes the current workflows for head and neck cancer patients, but also it's a novel idea in the sense that you're trying to ...

The FDA has approved a new drug for adults with a rare type of head and neck cancer known as non-keratinizing nasopharyngeal carcinoma (NPC).

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...

Find out what you need to know about your neck muscles and their function. Learn the signs of injury and how to keep these muscles healthy.

While fatigue in neck muscles has long been suspected of causing pain, the actual mechanical changes in the spine and muscles that precede weakness remain an outstanding question.